RSV Monoclonal Antibody Nirsevimab Highly Effective in Phase 3 Trial

The investigational long-acting monoclonal antibody Nirsevimab showed 74.5% efficacy against medically attended lower respiratory tract infections caused by RSV in healthy infants.